The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.c

Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

Publications

Colbenson GA, Olson EM, Nelson DR

61-Year-Old Man With Shortness of Breath and Cough.

Mayo Clinic proceedings 2021 Jul 02;; — 2021 Jul 02

Kalra SS, Trillo C, Papierniak E

Ustekinumab Associated with Chronic Eosinophilic Pneumonia.

The Journal of asthma : official journal of the Association for the Care of Asthma 2020 Sep 22;;1-6 — 2020 Sep 22 — 1-6

Brinker A, Cheng C, Chan V

Association of Noninfectious Pneumonia With Ustekinumab Use.

JAMA dermatology 2018 Dec 12;; — 2018 Dec 12

Amy de la Bretèque M, Appere-De Vecchi C, Zeboulon C, Zaien I, Sigal ML, Mahé E

[Ustekinumab-induced eosinophilic pneumonia during the course of ustekinumab therapy for plaque psoriasis].

Annales de dermatologie et de venereologie 2015 Mar;142;193-6 — 2015 Mar — 193-6

Yashiro M, Maejima H, Taniguchi T, Katsuoka K, Kimura M, Wada M

Psoriasis vulgaris complicated by eosinophilic pneumonia during ustekinumab treatment.

European journal of dermatology : EJD 2013 May-Jun;23;396-7 — 2013 May-Jun — 396-7